Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00947856 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study (NCT00947856)

Trial Description
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (also known as SGN-35) in patients who have previously participated in an brentuximab vedotin study.

This trial is sponsored by Millennium PharmaceuticalsSeattle Genetics. [1]

Study Data

  • Conditions:
    • Hodgkin Disease
    • Anaplastic Large Cell Lymphoma
    • Non-Hodgkin Lymphoma
  • Interventions:
  • Phase: II
  • Enrollment: 110
  • Start: July 2009
  • Completion: March 2013
  • Last verified: May 2014

Study Schematic

(CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 16, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar